Dallas Ebola patient Thomas Duncan is now receiving an experimental drug called brincidofovir, a broad-spectrum antiviral that has appeared promising against Ebola in test tube studies. The drug is currently being tested on animals but has not been tested on humans.
Duncan is still in critical condition, according to Texas Health Presbyterian Hospital.
The drug is an oral medication developed by the biopharmaceutical company Chimerix Inc. The company says the drug received Emergency Investigational New Drug Applications (EIND) from the Food and Drug Administration on Monday morning and it is working with the agency to open a clinical trial. The request for use of investigational drugs can be made by physicians. So far, this drug has only shown effectiveness against the virus in vitro.
Centers for Disease Control and Prevention director Dr. Tom Frieden previously said the decision of whether to treat Duncan with any experimental drugs would be left up Duncan, his family and his doctors.
More Must-Reads From TIME
- The 100 Most Influential People of 2024
- The Revolution of Yulia Navalnaya
- 6 Compliments That Land Every Time
- What's the Deal With the Bitcoin Halving?
- If You're Dating Right Now , You're Brave: Column
- The AI That Could Heal a Divided Internet
- Fallout Is a Brilliant Model for the Future of Video Game Adaptations
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
Contact us at letters@time.com